Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis

被引：0
|
作者：
Hauser, Stephen L. [1 ]
Kappos, Ludwig [2 ]
Montalban, Xavier [3 ,4 ]
Craveiro, Licinio [5 ]
Hughes, Richard [5 ]
Prajapati, Kalpesh [6 ]
Koendgen, Harold [5 ]
Pradhan, Ashish [7 ]
Wolinsky, Jerry S. [8 ]
机构：
[1] Univ Calif San Francisco, San Francisco, CA USA
[2] Univ Basel, Univ Hosp Basel, Basel, Switzerland
[3] Univ Toronto, Div Neurol, Toronto, ON, Canada
[4] Vall dHebron Univ Hosp, Barcelona, Spain
[5] F Hoffmann La Roche Ltd, Basel, Switzerland
[6] GCE Solut Inc, Bloomington, IL USA
[7] Genentech Inc, San Francisco, CA 94080 USA
[8] Univ Texas Hlth Sci Ctr Houston UTHlth, McGovern Med Sch, Houston, TX USA
来源：
NEUROLOGY | 2020年 / 94卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
1147
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Beyond ocrelizumab in primary progressive multiple sclerosis
    Thomas Williams
    Jeremy Chataway
    Nature Reviews Neurology, 2022, 18 : 641 - 642
  • [32] Beyond ocrelizumab in primary progressive multiple sclerosis
    Williams, Thomas
    Chataway, Jeremy
    NATURE REVIEWS NEUROLOGY, 2022, 18 (11) : 641 - 642
  • [33] Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal
    Martins, Paulo
    Vandewalle, Bjorn
    Felix, Jorge
    Capela, Carlos M.
    Cerqueira, Joao J.
    Salgado, Antonio, V
    Ferreira, Diana G.
    Monteiro, Isabel
    PHARMACOECONOMICS-OPEN, 2023, 7 (02) : 229 - 241
  • [34] Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal
    Paulo Martins
    Björn Vandewalle
    Jorge Félix
    Carlos M. Capela
    João J. Cerqueira
    António V. Salgado
    Diana G. Ferreira
    Isabel Monteiro
    PharmacoEconomics - Open, 2023, 7 : 229 - 241
  • [35] Real world evidence with Ocrelizumab in progressive and relapsing multiple sclerosis
    Meca-Lallana, V.
    Diaz-Perez, C.
    Aguirre, C.
    del Rio, B.
    Martin, R.
    del Rio, B.
    Carabajal, E.
    Vivancos, J.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 97 - 98
  • [36] Comparison of cognitive functions in relapsing and progressive multiple sclerosis patients on ocrelizumab treatment
    Ozakbas, S.
    Ozcelik, S.
    Kaya, E.
    Ozdogar, T.
    Sagici, O.
    Baba, C.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (2_SUPPL) : 9 - 9
  • [37] Reduction of intrathecal immunoglobulin levels with ocrelizumab treatment in relapsing and primary progressive multiple sclerosis
    Weber, Martin
    Gelfand, Jeffrey
    Bar-Or, Amit
    Cameron, Briana
    Ramesh, Akshaya
    Anania, Veronica
    von Budingen, H. -Christian
    Herman, Ann
    Spiciarich, David
    Grondey, Katja
    Schuetz, Konstantin
    Winger, Ryan
    Jia, Xiaoming
    Harp, Christopher
    Cross, Anne
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 570 - 571
  • [38] Relapsing-remitting and primary progressive multiple sclerosis treated with ocrelizumab: A comparative study
    de Antonio, Luis A. Rodriguez
    Cuberta-Gonzalez, Ines
    Garcia-Castanon, Inmaculada
    Oreja-Guevara, Celia
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 69
  • [39] Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
    Benjamin Turner
    Bruce A. C. Cree
    Ludwig Kappos
    Xavier Montalban
    Caroline Papeix
    Jerry S. Wolinsky
    Regine Buffels
    Damian Fiore
    Hideki Garren
    Jian Han
    Stephen L. Hauser
    Journal of Neurology, 2019, 266 : 1182 - 1193
  • [40] Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
    Montalban, X.
    Hauser, S. L.
    Kappos, L.
    Arnold, D. L.
    Bar-Or, A.
    Comi, G.
    de Seze, J.
    Giovannoni, G.
    Hartung, H. -P.
    Hemmer, B.
    Lublin, F.
    Rammohan, K. W.
    Selmaj, K.
    Traboulsee, A.
    Sauter, A.
    Masterman, D.
    Fontoura, P.
    Belachew, S.
    Garren, H.
    Mairon, N.
    Chin, P.
    Wolinsky, J. S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (03): : 209 - 220
12345